| Literature DB >> 27823607 |
Meng H Tan1, Hussain Alquraini2, Kara Mizokami-Stout2, Mark MacEachern3.
Abstract
Metformin is the recommended first-line oral glucose-lowering drug initiated to control hyperglycemia in type 2 diabetes mellitus. It acts in the liver, small intestines, and skeletal muscles with its major effect on decreasing hepatic gluconeogenesis. It is safe, inexpensive, and weight neutral and can be associated with weight loss. It can reduce microvascular complication risk and its use is associated with a lower cardiovascular mortality compared with sulfonylurea therapy. It is also used to delay the onset of type 2 diabetes mellitus, in treating gestational diabetes, and in women with polycystic ovary syndrome.Entities:
Keywords: Delaying onset of type 2 diabetes mellitus; Gestational diabetes; Glucose-lowering drug; Metformin; Polycystic ovary syndrome; Type 2 diabetes mellitus
Mesh:
Substances:
Year: 2016 PMID: 27823607 DOI: 10.1016/j.ecl.2016.06.008
Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN: 0889-8529 Impact factor: 4.741